Brain imaging in the study of Alzheimer's disease
暂无分享,去创建一个
[1] Kewei Chen,et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. , 2011, Journal of Alzheimer's disease : JAD.
[2] Benjamin J. Shannon,et al. Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory , 2005, The Journal of Neuroscience.
[3] M F Weiner,et al. Brain blood flow in the dementias: SPECT with histopathologic correlation in 54 patients. , 1997, Radiology.
[4] W. M. van der Flier,et al. Detection of Alzheimer Pathology In Vivo Using Both 11C-PIB and 18F-FDDNP PET , 2009, Journal of Nuclear Medicine.
[5] S. Thibodeau,et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.
[6] G. Alexander,et al. Declining brain activity in cognitively normal apolipoprotein E ɛ4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[7] G. Alexander,et al. Correlations between apolipoprotein E ε4 gene dose and brain-imaging measurements of regional hypometabolism , 2005 .
[8] C. Rowe,et al. Relationship between atrophy and β‐amyloid deposition in Alzheimer disease , 2010, Annals of neurology.
[9] Agneta Nordberg,et al. Target-Specific PET Probes for Neurodegenerative Disorders Related to Dementia , 2010, The Journal of Nuclear Medicine.
[10] Francisco Lopera,et al. Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease , 2010, Annals of neurology.
[11] G. Small,et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[12] B L Holman,et al. The scintigraphic appearance of Alzheimer's disease: a prospective study using technetium-99m-HMPAO SPECT. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[13] G. Alexander,et al. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.
[14] Julie C Price,et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.
[15] Nick C Fox,et al. Conversion of amyloid positive and negative MCI to AD over 3 years , 2009, Neurology.
[16] C. Rowe,et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.
[17] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[18] Nick C Fox,et al. Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.
[19] F Barkhof,et al. Incidence of cerebral microbleeds , 2010, Neurology.
[20] S Minoshima,et al. Cerebral glucose metabolism in patients with AD and different APOE genotypes , 2005, Neurology.
[21] G. Alexander,et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[22] W. Jagust,et al. Longitudinal studies of regional cerebral metabolism in Alzheimer's disease , 1988, Neurology.
[23] Alan Carpenter,et al. Relationship between regional amyloid levels and cognitive performance in healthy controls, MCI subjects, and patients with alzheimer's: Phase II results from a florpiramine F18 PET imaging study , 2009, Alzheimer's & Dementia.
[24] Jonathan K. Foster,et al. Fluoro-2-Deoxy-D-Glucose (FDG)-PET in APOEε4 Carriers in the Australian Population , 2008 .
[25] Satvinder S Dhaliwal,et al. Fluoro-2-deoxy-D-glucose (FDG)-PET in APOEepsilon4 carriers in the Australian population. , 2008, Journal of Alzheimer's disease : JAD.
[26] Gina N. LaRossa,et al. [11C]PIB in a nondemented population , 2006, Neurology.
[27] J. Haxby,et al. Relations between Neuropsychological and Cerebral Metabolic Asymmetries in Early Alzheimer's Disease , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[28] E G Tangalos,et al. 1H MR spectroscopy in common dementias , 2004, Neurology.
[29] N. Schuff,et al. Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia. , 2006, Brain : a journal of neurology.
[30] Martin Rossor,et al. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study , 2008, Neurobiology of Disease.
[31] G L Shulman,et al. INAUGURAL ARTICLE by a Recently Elected Academy Member:A default mode of brain function , 2001 .
[32] Brian J Bacskai,et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. , 2002, Bioorganic & medicinal chemistry letters.
[33] Gwenn S. Smith,et al. EARLY MARKER FOR ALZHEIMER'S DISEASE: THE ATROPHIC HIPPOCAMPUS , 1989, The Lancet.
[34] J. Hoffman,et al. FDG PET imaging in patients with pathologically verified dementia. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[35] B. Miller,et al. CME Practice parameter : Diagnosis of dementia ( an evidence-based review ) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .
[36] W. Markesbery,et al. Hippocampal volume as an index of Alzheimer neuropathology: Findings from the Nun Study , 2002, Neurology.
[37] Vince D. Calhoun,et al. Alterations in Memory Networks in Mild Cognitive Impairment and Alzheimer's Disease: An Independent Component Analysis , 2006, The Journal of Neuroscience.
[38] S. DeKosky,et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.
[39] A Hofman,et al. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[40] Andrei G. Vlassenko,et al. Regional aerobic glycolysis in the human brain , 2010, Proceedings of the National Academy of Sciences.
[41] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[42] D. Bennett,et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer’s disease☆ ☆ This research was supported by grants P01 AG09466 and P30 AG10161 from the National Institute on Aging, National Institutes of Health. , 2001, Neurobiology of Aging.
[43] Z Walker,et al. Microglial activation and amyloid deposition in mild cognitive impairment , 2009, Neurology.
[44] C. Jack,et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.
[45] J. Mazziotta,et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[46] Nick C Fox,et al. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.
[47] Jeffrey A. James,et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.
[48] Roger N Gunn,et al. In-vivo measurement of activated microglia in dementia , 2001, The Lancet.
[49] Yaakov Stern,et al. Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. , 2008, Archives of neurology.
[50] Trey Hedden. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden , 2010, Alzheimer's & Dementia.
[51] Matthias J. Müller,et al. Predicting conversion to dementia in mild cognitive impairment by volumetric and diffusivity measurements of the hippocampus , 2006, Psychiatry Research: Neuroimaging.
[52] Mark S. Cohen,et al. Patterns of brain activation in people at risk for Alzheimer's disease. , 2000, The New England journal of medicine.
[53] B. Miller,et al. Neurodegenerative Diseases Target Large-Scale Human Brain Networks , 2009, Neuron.
[54] Deborah Gustafson,et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. , 2004, Archives of neurology.
[55] C. Jack,et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.
[56] J. Morris,et al. Functional deactivations: Change with age and dementia of the Alzheimer type , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[57] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[58] Mark A Mintun,et al. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. , 2009, Archives of neurology.
[59] et al.,et al. Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET , 2002, NeuroImage.
[60] B. L. Miller,et al. Frontal lobe degeneration , 1991, Neurology.
[61] C. Rowe,et al. Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.
[62] J. Haxby,et al. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. , 1990, Archives of neurology.
[63] Laura Fratiglioni,et al. Late-life engagement in social and leisure activities is associated with a decreased risk of dementia: a longitudinal study from the Kungsholmen project. , 2002, American journal of epidemiology.
[64] C. Jack,et al. Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2005, Alzheimer's & Dementia.
[65] G. Alexander,et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.
[66] E. Salmon,et al. 18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.
[67] P Sachdev,et al. Magnetic resonance spectroscopy in AD , 2001, Neurology.
[68] Christer Halldin,et al. Radiopharmaceuticals for positron emission tomography investigations of Alzheimer’s disease , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[69] H. Engler,et al. PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.
[70] Mony J. de Leon,et al. Hypometabolism and Altered Cerebrospinal Fluid Markers in Normal Apolipoprotein E E4 Carriers with Subjective Memory Complaints , 2008, Biological Psychiatry.
[71] J. Baron,et al. Dissociating atrophy and hypometabolism impact on episodic memory in mild cognitive impairment. , 2003, Brain : a journal of neurology.
[72] Simon A. Moss,et al. b -amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease , 2007 .
[73] Amy J. Jak,et al. Differential Cross-Sectional and Longitudinal Impact of APOE Genotype on Hippocampal Volumes in Nondemented Older Adults , 2007, Dementia and Geriatric Cognitive Disorders.
[74] C. DeCarli,et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. , 2007, Brain : a journal of neurology.
[75] R. Sperling,et al. Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline , 2010, Neurology.
[76] C. Jack,et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI , 2005, Neurology.
[77] Chengjie Xiong,et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease , 2011, Alzheimer's Research & Therapy.
[78] A. Convit,et al. Reduced hippocampal metabolism in MCI and AD , 2005, Neurology.
[79] Cindee M. Madison,et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. , 2009, Brain : a journal of neurology.
[80] P. Zandi,et al. No advantage of Aβ42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies , 2008, Neurology.
[81] L. Thurfjell,et al. Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease , 2009, Journal of Nuclear Medicine.
[82] Mayo Clinic,et al. PRECLINICAL EVIDENCE OF ALZHEIMER’S DISEASE IN PERSONS HOMOZYGOUS FOR THE , 2000 .
[83] H. Rusinek,et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer’s disease , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[84] J. Schneider,et al. Neuropathology of older persons without cognitive impairment from two community-based studies , 2006, Neurology.
[85] Majaz Moonis,et al. Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees , 2007, The Journal of Neuroscience.
[86] Anatol C. Kreitzer,et al. Aberrant Excitatory Neuronal Activity and Compensatory Remodeling of Inhibitory Hippocampal Circuits in Mouse Models of Alzheimer's Disease , 2007, Neuron.
[87] C. Rowe,et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.
[88] W. Jagust,et al. Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia , 2008, Annals of neurology.
[89] B L Holman,et al. Preclinical prediction of Alzheimer's disease using SPECT , 1998, Neurology.
[90] Lars Farde,et al. Characterization of AZD4694, a novel fluorinated Aβ plaque neuroimaging PET radioligand , 2010, Journal of neurochemistry.
[91] et al.,et al. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI) , 2009, NeuroImage.
[92] M. Albert,et al. Medial temporal lobe function and structure in mild cognitive impairment , 2004, Annals of neurology.
[93] Cindee M. Madison,et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI , 2011, Neurobiology of Aging.
[94] K. Herholz,et al. Functional interactions of the entorhinal cortex: an 18F-FDG PET study on normal aging and Alzheimer's disease. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[95] M D Devous,et al. SPECT Study of Regional Cerebral Blood Flow in Alzheimer Disease , 1986, Journal of computer assisted tomography.
[96] William J. Jagust,et al. Lifespan brain activity, β-amyloid, and Alzheimer's disease , 2011, Trends in Cognitive Sciences.
[97] M. Viitanen,et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment , 2007, Neurology.
[98] D. Perani,et al. MCI conversion to dementia and the APOE genotype , 2004, Neurology.
[99] N. Foster,et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease , 1997, Annals of neurology.
[100] Takahira Yamauchi,et al. Abnormalities of the uncinate fasciculus and posterior cingulate fasciculus in mild cognitive impairment and early Alzheimer's disease: A diffusion tensor tractography study , 2009, Brain Research.
[101] Richard J. Caselli,et al. Correlations Between Apolipoprotein E ε4 Gene Dose and Whole Brain Atrophy Rates , 2007 .
[102] Timo Grimmer,et al. Clinical severity of Alzheimer's disease is associated with PIB uptake in PET , 2009, Neurobiology of Aging.
[103] L. Ferrucci,et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB , 2010, Neurology.
[104] Keith A. Johnson,et al. Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease , 2009, The Journal of Neuroscience.
[105] Michael E Phelps,et al. Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia. , 2009, Archives of general psychiatry.
[106] A Hofman,et al. Hippocampal, amygdalar, and global brain atrophy in different apolipoprotein E genotypes , 2002, Neurology.
[107] J. Kaye,et al. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia , 1997, Neurology.
[108] Keith A. Johnson,et al. Cognition, Reserve, and Amyloid Deposition in Normal Aging , 2009, Annals of neurology.
[109] J. Baron,et al. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment , 2005, Neurocase.
[110] A. Convit,et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD , 2001, Neurobiology of Aging.
[111] Eric Westman,et al. Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation , 2011, Neurobiology of Aging.
[112] J. Baron,et al. Mild cognitive impairment , 2003, Neurology.
[113] C. Jack,et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD , 2004, Neurology.
[114] G. Linazasoro,et al. IMAGING β-AMYLOID BURDEN IN AGING AND DEMENTIA , 2008, Neurology.
[115] Jeffrey A. James,et al. Amyloid imaging in mild cognitive impairment subtypes , 2009, Annals of neurology.
[116] N. Foster,et al. Alzheimer's disease , 1983, Neurology.
[117] Hidekazu Tomimoto,et al. SILENT ISCHEMIC INFARCTS ARE ASSOCIATED WITH HEMORRHAGE BURDEN IN CEREBRAL AMYLOID ANGIOPATHY , 2010, Neurology.
[118] C. Jack,et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.
[119] Julie Price,et al. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. , 2009, Archives of neurology.
[120] J. Baron,et al. In Vivo Mapping of Gray Matter Loss with Voxel-Based Morphometry in Mild Alzheimer's Disease , 2001, NeuroImage.
[121] M. D. de Leon,et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[122] P. Scheltens,et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.
[123] D. Davies,et al. MYOCARDIAL DISORDERS IN THE ELDERLY. , 1963, Lancet.
[124] Rachel L. Mistur,et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[125] John X. Morris,et al. Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ) deposition , 2010, Proceedings of the National Academy of Sciences.
[126] Yaakov Stern,et al. Physical activity, diet, and risk of Alzheimer disease. , 2009, JAMA.
[127] N. Schuff,et al. Headache and cerebral venous air embolism , 2007, Neurology.
[128] Anders M. Fjell,et al. Accelerated age-related cortical thinning in healthy carriers of apolipoprotein E ɛ4 , 2008, Neurobiology of Aging.
[129] Cindee M. Madison,et al. Comparing predictors of conversion and decline in mild cognitive impairment , 2010, Neurology.
[130] P. Tariot,et al. Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. , 2010, Biomarkers in medicine.
[131] K. Ball,et al. Long-term effects of cognitive training on everyday functional outcomes in older adults. , 2006, JAMA.
[132] Alistair Burns,et al. Observations on the brains of demented old people. B.E. Tomlinson, G. Blessed and M. Roth, Journal of the Neurological Sciences (1970) 11, 205–242; (1968) 7, 331–356 , 1997 .
[133] P. Dupont,et al. Abeta amyloid deposition in the language system and how the brain responds. , 2007, Brain : a journal of neurology.
[134] D. Harvey,et al. Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD , 2006, Neurology.
[135] Brigitte Landeau,et al. Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: A longitudinal MRI study , 2005, NeuroImage.
[136] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup , 2011 .
[137] J. Foster,et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. , 2008, JAMA.
[138] S. Minoshima,et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease , 1999, Neurology.
[139] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[140] Elena Salvatore,et al. In Vivo Imaging of Neurotransmission and Brain Receptors in Dementia , 2008, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[141] T. J. Grabowski,et al. Two-year followup of amyloid deposition in patients with Alzheimer's disease , 2007 .
[142] G. Fein,et al. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease , 1997, Neurology.
[143] F. Schmitt,et al. Assessing Utility of Single Photon Emission Computed Tomography (SPECT) Scan in Alzheimer Disease: Correlation with Cognitive Severity , 1990, Alzheimer disease and associated disorders.
[144] A. Fagan,et al. APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging , 2010, Annals of neurology.
[145] Klaus P. Ebmeier,et al. A meta-analysis of diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease , 2011, Neurobiology of Aging.
[146] H Lundqvist,et al. Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment. , 1997, Dementia and geriatric cognitive disorders.
[147] R. Coleman,et al. Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.
[148] F. Fazio,et al. Impairment of Neocortical Metabolism Predicts Progression in Alzheimer’s Disease , 1999, Dementia and Geriatric Cognitive Disorders.
[149] Michael W. Weiner,et al. Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative , 2010, NeuroImage.
[150] G. Alexander,et al. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. , 2002, The American journal of psychiatry.
[151] D. Head,et al. Amyloid Plaques Disrupt Resting State Default Mode Network Connectivity in Cognitively Normal Elderly , 2010, Biological Psychiatry.
[152] Lenore J Launer,et al. Reducing the Risk of Dementia: Efficacy of Long-Term Treatment of Hypertension , 2006, Stroke.
[153] B. Långström,et al. The use of PET in Alzheimer disease , 2010, Nature Reviews Neurology.
[154] D. Bennett,et al. White matter changes in mild cognitive impairment and AD: A diffusion tensor imaging study , 2006, Neurobiology of Aging.
[155] J C Mazziotta,et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. , 1995, JAMA.
[156] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[157] E. Tangalos,et al. CME Practice parameter: , 2022 .
[158] Cynthia K Thompson,et al. Anatomy of Language Impairments in Primary Progressive Aphasia , 2011, The Journal of Neuroscience.
[159] Paul M. Thompson,et al. Characterizing Alzheimer's disease using a hypometabolic convergence index , 2011, NeuroImage.
[160] Keith A. Johnson,et al. Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia , 2009, Neuron.
[161] E. Sullivan,et al. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease , 2000, The Lancet.
[162] Nick C. Fox,et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroup , 2011 .
[163] A. Drzezga,et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[164] A. Fagan,et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. , 2009, Archives of neurology.
[165] J. Morris,et al. The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals , 2008, Cerebral cortex.
[166] P. Bartenstein,et al. Association between Cognitive Performance and Cortical Glucose Metabolism in Patients with Mild Alzheimer’s Disease , 2005, Dementia and Geriatric Cognitive Disorders.
[167] Andrew J. Saykin,et al. Regional brain atrophy in cognitively intact adults with a single APOE ε4 allele , 2006, Neurology.
[168] Dong Young Lee,et al. Topographic Patterns of Brain Functional Impairment Progression According to Clinical Severity Staging in 116 Alzheimer Disease Patients: FDG-PET Study , 2007, Alzheimer disease and associated disorders.
[169] Eric M. Reiman,et al. Brain Imaging in the Evaluation of Putative Alzheimer’s Disease-Slowing, Risk-Reducing and Prevention Therapies , 2009 .
[170] Deanna Greenstein,et al. Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study , 2007, The Lancet Neurology.
[171] Tyler E. Benedum,et al. Preclinical Properties of 18F-AV-45: A PET Agent for Aβ Plaques in the Brain , 2009, Journal of Nuclear Medicine.
[172] C. Rowe,et al. Characterization of PiB Binding to White Matter in Alzheimer Disease and Other Dementias , 2009, Journal of Nuclear Medicine.
[173] Masanori Nakagawa,et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. , 2009, Archives of neurology.
[174] Lars T Westlye,et al. Accelerated age-related cortical thinning in healthy carriers of apolipoprotein E epsilon 4. , 2008, Neurobiology of aging.
[175] C. Jack,et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment , 1999, Neurology.
[176] Richard S. J. Frackowiak,et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease , 1995, Neuroscience Letters.
[177] Michael D. Greicius,et al. Relationships between β-amyloid and functional connectivity in different components of the default mode network in aging. , 2011, Cerebral cortex.
[178] Danielle J. Harvey,et al. The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes , 2010, Alzheimer's & Dementia.
[179] R. V. Van Heertum,et al. SPECT perfusion imaging in the diagnosis of Alzheimer’s disease , 2001, Neurology.
[180] J. Morris,et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup , 2011 .
[181] Gina N. LaRossa,et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.
[182] C. Rowe,et al. Imaging β-amyloid burden in aging and dementia , 2007, Neurology.
[183] M. Greicius,et al. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: Evidence from functional MRI , 2004, Proc. Natl. Acad. Sci. USA.
[184] Daniel Bandy,et al. Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele. , 2010, Archives of neurology.
[185] Susan M Resnick,et al. In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. , 2011, Archives of neurology.
[186] V. Calhoun,et al. Default mode network connectivity in stable vs progressive mild cognitive impairment , 2011, Neurology.
[187] Nick C Fox,et al. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. , 2000, Archives of neurology.